MedTrace Logo

Precision Medicine to Predict the Trajectory of Liver Cirrhosis: Prospective Cohort Study

NCT05899309 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-06-12

No results posted yet for this study

Summary

Preventing decompensation is a key endpoint in the management of compensate cirrhosis patients. The known factors that increases the risk of decompensation include the presence of clinically significant portal hypertension (CSPH) and the control of primary etiology of cirrhosis. Other factors which may influence the progression of cirrhosis included the presence of metabolic syndrome (diabetes mellitus and obesity), frailty, concomitant medications (statin, non-selective beta-blocker) were not well understood. Investigators aim to perform a pilot, observational study to study various baseline factors in relation to the clinical outcome of cirrhosis patients in a prospective follow up.

Conditions

Interventions

DIAGNOSTIC_TEST

liver and spleen stiffness test and laboratory test

Diagnosis of cirrhosis can be based on liver biopsy,radiological ,clinical or liver stiffness measurement (LMS)

Sponsors & Collaborators

  • Changi General Hospital

    lead OTHER

Principal Investigators

  • Yu Jun Wong, MD · Changi General Hospital

Eligibility

Min Age
21 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-23
Primary Completion
2023-12-12
Completion
2024-09-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05899309 on ClinicalTrials.gov